On September 10, LightPath Technologies (NASDAQ:LPTH) reported fiscal fourth-quarter and full-year results that turned a multiyear strategic bet into a financial statement. Revenue nearly doubled for the year, margins expanded, and the company walked away from its last manufacturing ties to China. For a small-cap optics supplier that spent years explaining a strategy, this was the quarter the strategy started explaining itself.
A Backlog That Keeps Outrunning Itself
Annual revenue climbed 92.7% to $71.7 million from $37.2 million, and the fourth quarter alone hit a record $21.2 million, up 73.8% year over year. That growth is not just volume. Full-year gross margin expanded to 36% from 27.2%, and the fourth quarter came in even higher at 39.4%, because assemblies, modules and cameras now make up 44% of annual sales instead of being sold as raw components.
CEO Sam Rubin said the shift reflects both a change in what LightPath sells and better execution on what it already made, noting every one of its four product groups improved margin for the year. Backlog finished at $110.9 million, up 197% from $37.4 million a year earlier, with $85.6 million of it scheduled for delivery within 12 months. Weeks after the fiscal year closed, the company booked another $24 million in counter-UAS orders, and some of those programs have already moved to monthly delivery cadences of tens of units.
LightPath also completed its exit from China, selling its subsidiary there for $4.5 million paid out over five years, leaving the company with no manufacturing footprint in a country that increasingly can’t supply the defense primes it depends on. That matters because defense programs face a deadline this decade to source optics away from covered nations, and qualification cycles run two to three years, meaning the sourcing decisions being made now will determine who wins contracts in 2029 and 2030.
Growing Pains Behind The Record Numbers
The company’s fourth-quarter net loss narrowed to $4.1 million from $7.1 million a year earlier, but full-year operating expenses jumped to $45.5 million from $22 million, and $15.6 million of that was a noncash charge tied to G5 Infrared outperforming the earnout targets set at acquisition. Management called that charge mostly behind the business now that the final G5 payout has been accrued for January 2027, but it is a reminder that acquisition accounting can swing the income statement even when operations are healthy.
Some of the programs LightPath is counting on are also slipping. Rubin said the Army pushed its Next Generation Short Range Interceptor timeline out by several months while it explores other options, and the redesign of G5’s cooled cameras to use the company’s Black Diamond glass instead of germanium is, in his words, “behind schedule,” even though the technical results look promising. He also flagged that detector lead times have stretched from roughly six months to ten months or more, a supply constraint that could slow how fast LightPath converts its backlog into shipped revenue.
Layered on top of that is a capital spending ramp: fiscal 2026 capital expenditures were $6.3 million, with $4.4 million of that in the fourth quarter alone, and management said fiscal 2027 spending will be higher still as it expands melting and assembly capacity across its US and Latvian sites.
Funds Pulling Back As Shorts Pile On
Hedge fund ownership of LightPath fell to 20 funds in the most recent quarter from 27 in the prior quarter, a pullback even as the company posted record results. Short interest sits at 15.44% of float, a level that points to a substantial bear camp betting against the stock. That combination suggests that skepticism has been building even as the headline numbers improved. It also sets up the kind of crowded short position that can move sharply if the backlog keeps converting into revenue at the pace management is projecting.
Where LightPath Goes From Here
LightPath enters fiscal 2027 with $93.2 million in cash, no meaningful debt, and a backlog that has grown for five straight quarters, but the company itself describes the year ahead as an execution test rather than a victory lap. For the bullish case to hold, LightPath needs to add manufacturing capacity fast enough to convert its order book without letting margins slip, and it needs delayed programs like NGSRI to eventually reach production. For the skeptics, the combination of falling hedge fund ownership, elevated short interest, and a business still working through earnout charges and stretched detector lead times leaves real room for execution to disappoint.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
